Short Interest in Heart Test Laboratories, Inc. (NASDAQ:HSCS) Rises By 6.1%

Heart Test Laboratories, Inc. (NASDAQ:HSCS) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 31,200 shares, an increase of 6.1% from the December 15th total of 29,400 shares. Based on an average daily trading volume, of 42,900 shares, the short-interest ratio is currently 0.7 days. Approximately 3.8% of the company’s shares are sold short.

Heart Test Laboratories Trading Up 4.2 %

Heart Test Laboratories stock traded up $0.14 during trading hours on Friday, reaching $3.47. The stock had a trading volume of 10,113 shares, compared to its average volume of 53,127. The company has a fifty day simple moving average of $3.42 and a 200-day simple moving average of $3.52. Heart Test Laboratories has a 52 week low of $2.36 and a 52 week high of $18.50. The stock has a market cap of $3.40 million, a PE ratio of -0.44 and a beta of 2.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.52.

Heart Test Laboratories (NASDAQ:HSCS) last posted its earnings results on Monday, December 16th. The company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.30) by $0.03. During the same period in the prior year, the firm earned ($15.92) earnings per share. Analysts forecast that Heart Test Laboratories will post -9.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Ascendiant Capital Markets reissued a “buy” rating and issued a $15.00 target price on shares of Heart Test Laboratories in a research note on Monday, September 23rd. Maxim Group reiterated a “buy” rating and issued a $12.00 price objective on shares of Heart Test Laboratories in a research report on Wednesday, December 18th.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.